))
Episode 58: Samarendra Mohanty - President & CSO, Nanoscope Therapeutics
Manage episode 408954867 series 3526490
Contenuto fornito da Vial. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Vial o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Dr. Samar Mohanty, president and CSO of Nanoscope Therapeutics joins us to shed light on the revolutionary gene therapy that's giving hope to individuals with retinal degenerative diseases by pioneering a treatment that can re-sensitize the retina to detect low light levels. We open the curtains on their groundbreaking multi-characteristic opsins (MCOs), which have the potential to address all forms of retinal degeneration and restore vision in millions of visually impaired individuals.
First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.
Interested in being featured as a guest on First In Human? Please reach out to owen@vial.com.
🎧 Stay in the Loop!
For the latest news and updates, visit our website: https://vial.com
Follow us on social media for real-time insights:
Twitter: https://twitter.com/VialTrials
LinkedIn: https://www.linkedin.com/company/vialtrials
Capitoli
1. Episode 58: Samarendra Mohanty - President & CSO, Nanoscope Therapeutics (00:00:00)
2. Revolutionary Gene Therapy for Vision (00:00:06)
3. The Future of Retinal Gene Therapy (00:15:32)
62 episodi
Condividi
